Drugs in MeSH Category Anesthetics, Intravenous

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-004	May 1, 2023		RX	Yes	No	11,602,512
Bedford	MIDAZOLAM HYDROCHLORIDE	midazolam hydrochloride	INJECTABLE;INJECTION	075249-001	Jun 23, 2000		DISCN	No	No
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-001	May 1, 2023		RX	Yes	Yes	12,097,175		Y
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-001	May 1, 2023		RX	Yes	Yes	12,303,478
Neurelis Inc	VALTOCO	diazepam	SPRAY;NASAL	211635-001	Jan 10, 2020		RX	Yes	No	8,895,546		Y
Btcp Pharma	SUBSYS	fentanyl	SPRAY;SUBLINGUAL	202788-005	Jan 4, 2012		DISCN	Yes	No	9,642,797		Y
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-002	May 1, 2023		RX	Yes	No	11,826,335

Market Dynamics and Patent Landscape for NLM MeSH Class: Anesthetics, Intravenous

Last updated: June 24, 2026

Executive summary: NLM MeSH “Anesthetics, Intravenous” is dominated by generic-entry pressure around older IV anesthetics and by patent-protected next-gen delivery improvements in newer intravascular agents. Patent estates tend to cluster by (1) active-ingredient composition and (2) formulation or method-of-use coverage tied to controlled infusion, emulsion stability, or perioperative dosing regimens. Market share is shaped less by new approvals than by Orange Book–driven generic substitution, FDA labeling continuity, and ongoing Paragraph IV challenges. For investors and licensors, the highest-impact workstreams are: mapping Orange Book and exclusivity clocks for leading IV anesthetics, cataloging formulation and process patents that block AB-rated generics, and tracking district-court Paragraph IV litigation that drives first-filer settlement terms and launch timing.

---

Which intravenous anesthetic drugs dominate MeSH “Anesthetics, Intravenous” and how do patents shape market share?

The MeSH category includes IV anesthetics used for procedural sedation and general anesthesia. Commercially meaningful agents typically fall into three patent-behavior profiles:

1. Legacy IV anesthetics with mature patent status
   Market dynamics skew toward low-cost multisource generics, with patent landscapes dominated by older composition-of-matter expiries and limited remaining enforcement tied to narrow formulation/process patents.

2. Newer IV anesthetics with still-active exclusivity and method/formulation patents
   These show tighter barriers to “true” interchangeability because generics must match not only API but also critical formulation properties (solubility, particle size distribution, pH, osmolarity, emulsion stability, and reconstitution characteristics).

3. IV anesthetics with device-adjacent or delivery-adjacent claims
   Where administration system or infusion workflow is part of claimed method-of-use or labeling-aligned protocols, generic substitution can lag even when composition patents expire.

How do generic and biosimilar dynamics differ for IV anesthetics?

Biosimilar frameworks apply only to biologics; IV anesthetics are typically small molecules. The competitive dynamic is generic substitution and 505(b)(2) reformulation rather than biosimilar entry. The patent risk is therefore concentrated in:

• Orange Book-listed patents for approved NDA/ANDA products
• 505(b)(2) exclusivity and patent reach-through for reformulations
• Paragraph IV litigation and settlement-controlled launch dates

---

What patents protect intravenous anesthetics: composition of matter, formulations, and method-of-use?

Direct answer: For IV anesthetics, the patent estate most often splits into three buckets that control generic entry probability: composition-of-matter, formulation/process, and method-of-use tied to perioperative dosing or administration.

Composition-of-matter patents

• Often anchor the longest exclusivity spans if the drug is still within primary patent life.
• Typically cover the active ingredient in a defined chemical structure space.

Generic impact: Once composition expires, generic risk accelerates unless formulation or method patents remain listed and enforceable.

Formulation and process patents

These are especially common for:

• IV emulsions
• Cremophor/solvent systems and their replacements
• Stabilized aqueous solutions
• Particle-size or micellar properties for poorly water-soluble agents
• Lyophilized or reconstitutable products with defined handling parameters

Generic impact: Even when the API is generic-available, formulation patents can force:

• delayed launches
• design-around (different solvent/emulsion system)
• 505(b)(2) pathways if the label is not fully duplicative

Method-of-use and dosing regimen patents

Coverage can be tied to:

• induction vs maintenance dosing schedules
• sedation depth endpoints
• patient population stratification (ASA class, age, comorbidities)
• perioperative monitoring and adjunct co-administration timing

Generic impact: If Orange Book patents list method-of-use tied to labeling, ANDA filers can face noninfringement and “label carve-out” arguments during litigation.

---

When do key intravenous anesthetic patents lose exclusivity and what clocks matter most?

Direct answer: Patent-to-launch timing is driven by four clocks: patent expiration, pediatric exclusivity, marketing exclusivity (NCE/505(b)(1), orphan if applicable), and the Orange Book patent listing status that controls 505(b)(2) and ANDA Paragraph IV exposure.

Exclusivity clocks that commonly extend competition delays

• Pediatric exclusivity (6 months): Adds time to marketing exclusivity for qualifying products; can shift settlement launch dates.
• New Chemical Entity (NCE) or New Product exclusivity (5 years for NDA under legacy rules): Affects 505(b)(2) and potentially 505(j) indirectly through data exclusivity logic.
• Orphan Drug exclusivity (7 years): Rare for broad perioperative anesthetics, but can occur in niche indications.

Patent expiration vs launch gap

Even after patent expiry, there can be a practical lag from:

• manufacturing scale-up
• stability studies for emulsion/solvent systems
• FDA labeling alignment
• settlement terms from earlier Paragraph IV cases

---

What is the Orange Book status of intravenous anesthetics and how many listed patents usually block generics?

Direct answer: Orange Book barriers for IV anesthetics frequently come from multi-patent listings per product, with the highest friction often from formulation and method patents rather than composition-only claims.

What “high-patent-count” typically means for barrier strength

In IV anesthetics, a “many-patents” Orange Book listing usually correlates with:

• multiple formulation/process continuations
• separate method-of-use claims aligned to induction or sedation depth
• device- or workflow-adjacent claims if dosing is tied to administration protocol

Generic risk: ANDA filers must carve out or design around the listed patents tied to approved labeling.

How to use Orange Book data for competitive modeling

For each leading IV anesthetic, the analytic approach is:

1. Identify all Orange Book listed patents tied to the NDA
2. Classify by claim type: composition vs formulation/process vs method-of-use
3. Map each patent’s expiration date and whether it is likely to be subject to terminal disclaimers or pediatric extensions
4. Overlay Paragraph IV litigation and settlement schedules to estimate real-world entry timing

---

Which companies are challenging patents for intravenous anesthetics via Paragraph IV and 505(b)(2)?

Direct answer: Patent challenges in IV anesthetics are typically filed by generic manufacturers with strong ANDA litigation track records and by 505(b)(2) filers seeking reformulation while staying close to the protected label. The strongest litigation clusters come from products where formulation or method patents remain listed late in the life cycle.

What patterns show up in IV anesthetic Paragraph IV litigation

• Challenges often target one or more formulation/process patents, leaving composition unchallenged because it is already expired or not the core barrier.
• Settlements frequently require:
  • narrow launch dates
  • label restrictions
  • supply or exclusivity-based compensation mechanisms

How to forecast challenger impact

Challenger value is highest when the filer can:

• pass bioequivalence or drug-product equivalence criteria
• avoid infringement on formulation/process claims by selecting alternative excipient or production steps
• secure a settlement that permits “at-risk” launch within a defined window

---

What generic entry risks exist for intravenous anesthetics with formulation patents (emulsions, solvents, and reconstitution systems)?

Direct answer: Formulation patents elevate entry risk because AB-rated generics must still meet product-quality attributes that can be tightly linked to the claimed formulation/process.

Key infringement vectors

• Particle size or droplet distribution requirements (for emulsions)
• Specific surfactant or solvent systems
• Stability windows and temperature excursion handling that the label requires
• Reconstitution volume and timing constraints

Design-around reality

In IV anesthetics, design-around is not always “just change excipients.” Excipients can change:

• solubility and local tolerability
• osmolality and pH
• adverse event profile
• regulatory acceptability for AB substitution

---

How does NLM MeSH Class “Anesthetics, Intravenous” patent strength compare by drug generation and delivery system?

Direct answer: The patent estate tends to be strongest for newer IV anesthetics with emulsion or formulation complexity and for molecules with active method-of-use claims in labeling. Weakest estates are typically older, straightforward solution products with composition-only coverage already expired.

Comparison framework by delivery system

• Emulsions: Highest formulation patent density, frequent late-life continuations.
• Concentrated aqueous solutions: Medium density, often anchored by formulation stability and buffering.
• Reconstitutable products: Often have process patents and method-of-use tied to handling.

---

What patent litigation affects IV intravenous anesthetics and how do settlements alter launch timing?

Direct answer: For IV anesthetics, settlement agreements usually determine when the first generic launches relative to the last non-expired Orange Book patent, even after legal victories. Litigation affects:

• “at-risk” launch decisions by challengers
• supply competition ramp timing
• label carve-outs that dictate AB substitution readiness

Common settlement structures in small-molecule generics

• Payment-for-delay (in jurisdictions where allowed historically) or business compensation through supply/marketing arrangements.
• Staggered entry where multiple ANDA filers are permitted to launch at different times based on court risk profiles.
• Label restrictions that preserve the brand’s differentiation while enabling generic availability without full substitution.

How to model settlement-driven launch

Practical modeling inputs:

• settlement effective date and “drop-dead” launch date
• which Orange Book patents remain asserted or withdrawn post-settlement
• whether the generic is required to omit labeling language that could reduce substitution rates

---

How do FDA regulatory pathways influence patent leverage for IV anesthetics (ANDA vs 505(b)(2))?

Direct answer: The FDA pathway dictates the evidence burden and therefore the degree of label-level alignment needed to avoid patent infringement tied to approved labeling.

ANDA (505(j))

• Designed for AB-rated generic substitution.
• Higher reliance on product sameness and bioequivalence standards.
• If formulation/method patents block labeling alignment, ANDA risk rises quickly.

505(b)(2)

• Used for reformulations or for products that rely on published literature or bridging studies.
• Often the route for “next-best” entries when formulation patents constrain straightforward ANDA.

Patent leverage: 505(b)(2) can still trigger challenges if it seeks to retain protected labeling claims or avoids design-arounds that would remove infringement risk.

---

Commercial outlook: which IV anesthetics face the highest revenue exposure from generic entry?

Direct answer: Revenue exposure clusters where (1) Orange Book lists near-expiry patents, (2) at least one Paragraph IV case is pending, and (3) the marketed drug has meaningful procedural volume such that price pressure would be immediate.

Revenue exposure indicators used in competitive forecasting

• Number of ANDAs and 505(b)(2) submissions tracked for the active ingredient
• Litigation docket activity in federal courts for the Orange Book-listed patents
• Settlement agreements that allow staged entry
• Brand product lifecycle maturity (age of NDA approval)
• Hospital formulary dynamics: whether substitution is “automatic” or requires purchasing committee actions

---

What patent estates block manufacturing and how do process patents affect IV anesthetic scale-up?

Direct answer: Process and manufacturing patents can block entry even when composition patents expire because they control upstream steps that are hard to reengineer without redesign of the product itself.

Typical process-related constraints

• emulsion preparation steps
• mixing order and mixing rates
• temperature control and sterilization parameters
• filtration, homogenization, or aseptic filling steps
• container closure system specifications

Business implication: A generic may win a patent case but still face time and cost delays to reach regulatory-quality manufacturing.

---

Key tables: how to map an IV anesthetic patent estate to generic entry scenarios

1) Patent-estate-to-entry probability map (template)

Barrier type	What patents cover	Main generic risk	Usual mitigation	Entry timing impact
Composition-of-matter	Active ingredient structure and variants	Low if expired	N/A	Months to years after expiry
Formulation/process	Solvent/emulsion/reconstitution stability, droplet properties, manufacturing steps	High	Design-around excipients/process; 505(b)(2) bridging	Often largest delay
Method-of-use	Dosing regimen tied to label	Medium to high	Carve-out labeling; noninfringement defenses	Depends on asserted patents
Exclusivity (data/marketing/pediatric)	NDA exclusivity and extensions	High early	Wait out exclusivity or switch to different bridging approach	Adds fixed time blocks

2) Settlement-informed launch scenario logic

Scenario	Likely outcome	What controls the date
Brand wins all asserted claims	Challenger delays	Court outcome + market strategy
Settlement with early date	Challenger launches at agreed schedule	Settlement launch term + labeling readiness
Partial settlement with label carve-outs	Launch occurs but substitution slower	Formulary and labeling scope

---

Key Takeaways

• IV anesthetic competition is primarily governed by Orange Book-listed formulation/process and method-of-use patents that protect product performance and label-aligned dosing, not by composition alone in most mature segments.
• Generic entry risk is highest for emulsion and formulation-complex products because design-around requires regulatory-acceptable changes to product attributes.
• Paragraph IV litigation and settlement agreements frequently determine real-world launch timing more than the calendar distance to patent expiry.
• For market and R&D planning, the fastest path to actionable decisions is a structured estate map: categorize Orange Book patents by claim type, overlay FDA pathway strategy (ANDA vs 505(b)(2)), and model settlement terms rather than relying on theoretical exclusivity end dates.

---

FAQs

1. How do formulation patents for IV anesthetic emulsions affect AB-rated generic substitution?
2. What is the Orange Book listing pattern for IV anesthetics: how many patents are typically method vs formulation?
3. When do pediatric exclusivity extensions typically shift first generic launch in IV anesthetics?
4. How do label carve-outs in IV anesthetic settlements impact hospital formulary adoption and price pressure?
5. What manufacturing process steps most commonly get claimed for IV anesthetic products and how do they drive regulatory timelines?

---

References (APA)

No sources were provided in the prompt.